Amgen's Cancer Strategy: A Multitude Of Modalities In Immuno-Oncology And Beyond

Like much of the biopharmaceutical industry, Amgen Inc.'s cancer drug strategy is shifting more and more toward immuno-oncology. But while it may not have a first-round checkpoint inhibitor, it has been a pioneer in at least two modes of immunotherapy. Not being married to a single therapeutic modality – antibody, small molecule, cell therapy, vaccine or otherwise – could turn out to be a long-term strength.

Thousand Oaks, California-based Amgen developed the first oncolytic virus – Imlygic (talimogene laherparepvec or T-VEC) – approved in the US. (Also see "Amgen’s Imlygic Approval A Milestone For Oncolytic...